中科微点-全球专利检索

  1. Login
  2. Sign Up

Search Results

695 records (took 0.03 seconds)

    NOVEL IL-17R-ECD MUTANTS
    21.
    发明申请
    NOVEL IL-17R-ECD MUTANTS 审中-公开
    新型IL-17R-ECD突变体

    公开(公告)号：WO2013011368A2

    公开(公告)日：2013-01-24

    申请号：PCT/IB2012/001400

    申请日：2012-07-18

    Applicant: TEVA PHARMACEUTICAL INDUSTRIES LTD. ,  AHARONI, Amir ,  ZARETZKY, Marianna

    Inventor： ZARETZKY, Marianna

    IPC: C07K14/54

    CPC classification number: C07K14/7155 ,  A61K38/00 ,  A61K38/1793 ,  A61K38/2006 ,  A61K45/06 ,  C07K14/54 ,  A61K2300/00

    Abstract: Provided are engineered soluble hIL-17RA receptors with high affinity to hIL-17 that inhibit downstream IL17A induced signaling events in cells. Also provided are methods of inhibiting hIL-17A induced secretion of CXCL1 and/or IL-6 in cells, as well as methods of treating inflammation and/or inflammatory disorders in a subject.

    Abstract translation: 提供了对hIL-17具有高亲和力的工程可溶性hIL-17RA受体，其抑制下游IL17A诱导细胞中的信号传导事件。 还提供了抑制细胞中hIL-17A诱导的CXCL1和/或IL-6分泌的方法，以及治疗受试者的炎症和/或炎症性疾病的方法。

    TREATMENT OF LUPUS ARTHRITIS USING LAQUINIMOD
    24.
    发明申请
    TREATMENT OF LUPUS ARTHRITIS USING LAQUINIMOD 审中-公开
    使用LAQUINIMOD治疗LUPUS ARTHRITIS

    公开(公告)号：WO2011109536A1

    公开(公告)日：2011-09-09

    申请号：PCT/US2011/026891

    申请日：2011-03-02

    Applicant: TEVA PHARMACEUTICAL INDUSTRIES LTD. ,  TEVA PHARMACEUTICALS USA, INC. ,  HAVIV, Asi ,  TARCIC, Nora

    Inventor： HAVIV, Asi ,  TARCIC, Nora

    IPC: A01N43/42 ,  A61K31/47

    CPC classification number: A61K31/4704 ,  A61K9/0053 ,  A61K45/06 ,  A61K2300/00

    Abstract: This invention provides a method of treating a subject afflicted with active lupus arthritis comprising periodically administering to the subject an amount of laqumimod or pharmaceutically acceptable salt thereof effective to treat the subject. This invention also provides laqumimod or pharmaceutically acceptable salt thereof for use in treating a subject afflicted with active lupus arthritis This invention further provides a pharmaceutical composition comprising an amount of laqumimod or pharmaceutically acceptable salt thereof for use in treating a subject afflicted with lupus arthritis.

    Abstract translation: 本发明提供了治疗患有活动性狼疮关节炎的受试者的方法，其包括向受试者施用一定量的有效治疗受试者的拉古霉素或其药学上可接受的盐。 本发明还提供了用于治疗患有活动性狼疮关节炎的受试者的拉古霉菌或其药学上可接受的盐。本发明还提供了一种药物组合物，其包含一定量的拉古霉素或其药学上可接受的盐，用于治疗患有狼疮关节炎的受试者。

    LOW FREQUENCY GLATIRAMER ACETATE THERAPY
    26.
    发明申请
    LOW FREQUENCY GLATIRAMER ACETATE THERAPY 审中-公开
    低频玻璃酸乙酯治疗

    公开(公告)号：WO2011022063A1

    公开(公告)日：2011-02-24

    申请号：PCT/US2010/002283

    申请日：2010-08-19

    Applicant: TEVA PHARMACEUTICAL INDUSTRIES LTD. ,  TEVA PHARMACEUTICALS USA, INC. ,  KLINGER, Ety

    Inventor： KLINGER, Ety

    IPC: A01N37/12 ,  A01N37/44 ,  A61K31/195

    CPC classification number: A61K9/0019 ,  A61K31/19 ,  A61K31/785 ,  A61K38/02 ,  A61K38/07 ,  A61K38/16

    Abstract: A method of alleviating a symptom of relapsing-remitting multiple sclerosis in a human patient suffering from relapsing-remitting multiple sclerosis or a patient who has experienced a first clinical episode and is determined to be at high risk of developing clinically definite multiple sclerosis comprising administering to the human patient three subcutaneous injections of a therapeutically effective dose of glatiramer acetate over a period of seven days with at least one day between every subcutaneous injection so as to thereby alleviate the symptom of the patient.

    Abstract translation: 一种减轻患有复发性多发性硬化的人类患者复发缓解多发性硬化的症状的方法或经历了第一次临床发作的患者，并被确定为具有发展为临床确定性多发性硬化的高风险的方法，其包括给予 人类患者在七天内三次皮下注射治疗有效剂量的醋酸格拉默，每次皮下注射至少一天，从而减轻患者的症状。

    PROCESS FOR THE PREPARATION AND PURIFICATION OF ETRAVIRINE AND INTERMEDIATES THEREOF
    27.
    发明申请
    PROCESS FOR THE PREPARATION AND PURIFICATION OF ETRAVIRINE AND INTERMEDIATES THEREOF 审中-公开
    肝素及其中间体的制备和纯化方法

    公开(公告)号：WO2011017079A1

    公开(公告)日：2011-02-10

    申请号：PCT/US2010/043329

    申请日：2010-07-27

    Applicant: TEVA PHARMACEUTICAL INDUSTRIES LTD. ,  TEVA PHARMACEUTICALS USA, INC. ,  KRIZMANIC, Irena ,  DOGAN, Jasna ,  MARINKOVIC, Marina ,  SEPELJ, Maja

    Inventor： KRIZMANIC, Irena ,  DOGAN, Jasna ,  MARINKOVIC, Marina ,  SEPELJ, Maja

    IPC: C07D239/34 ,  C07D239/42 ,  C07D239/48 ,  A61K31/505 ,  A61P31/18

    CPC classification number: C07D239/34 ,  A61K31/505 ,  C07D239/42 ,  C07D239/48

    Abstract: In one embodiment the present invention encompasses 4-(2,6-dichloropyrimidin-4-yloxy)-3,5-dimethylbenzonitrile ("ΕTHER"), 4-(4,6-dichloropyrimidm-2-yloxy)-3,5-dimethyl-benzonitrile ("ETHER C-2 isomer"), mixtures and salts thereof of. The present invention encompasses the use of ETHER and salts thereof to prepare Etravirine and Etravirine intermediates, and salts thereof. In another embodiment the present invention encompasses the use of ETHER and salts thereof to prepare debrometravirine ("DEBETV") and salts thereof. In yet another embodiment the present invention encompasses the use of ETHER and salts thereof to prepare 4-(6-chloro-2-(4-cyanophenylamino)pyrimidin-4-yloxy)-3,5-dimethyl-benzonitrile("ARCPBN") and salts thereof. The compound, 4-(2,6-dichloropyrimidin-4-yloxy)-3,5-dimethylbenzonitrile "ETHER" of formula (A) wherein n is either 0 or 1 and HA is an acid.

    Abstract translation: 在一个实施方案中，本发明包括4-（2,6-二氯嘧啶-4-基氧基）-3,5-二甲基苄腈（“？THER”），4-（4,6-二氯嘧啶-2-基氧基）-3,5 - 二甲基 - 苄腈（“ETHER C-2异构体”），其混合物和盐。 本发明包括ETHER及其盐在制备Etravirine和Etravirine中间体及其盐中的应用。 在另一个实施方案中，本发明包括ETHER及其盐在制备非曲马瑞林（“DEBETV”）及其盐中的用途。 在另一个实施方案中，本发明包括醚及其盐在制备4-（6-氯-2-（4-氰基苯基氨基）嘧啶-4-基氧基）-3,5-二甲基 - 苄腈（“ARCPBN”）中的用途， 及其盐。 化合物，式（A）的4-（2,6-二氯嘧啶-4-基氧基）-3,5-二甲基苄腈“ETHER”，其中n为0或1，HA为酸。

    PROGRAMMABLE STEAM TRAP APPARATUS
    29.
    发明申请
    PROGRAMMABLE STEAM TRAP APPARATUS 审中-公开
    可编程蒸汽装置

    公开(公告)号：WO2010134977A1

    公开(公告)日：2010-11-25

    申请号：PCT/US2010/001466

    申请日：2010-05-18

    Applicant: TEVA PHARMACEUTICAL INDUSTRIES LTD. ,  TEVA PHARMACEUTICALS USA, INC

    Inventor： ALONI, Yehoshua ,  FAHIMIPOOR, Oren

    IPC: F16T1/34

    CPC classification number: F16T1/48 ,  A61L2/07 ,  F16T1/00 ,  F16T1/02 ,  Y10T137/0396 ,  Y10T137/3003 ,  Y10T137/4266 ,  Y10T137/7737

    Abstract: An apparatus and a method for removing condensate and unwanted gas from vapor/liquid systems while preventing steam loss are provided. The steam trap apparatus replaces the automatic valve type steam trap with an efficient, controllable, and programmable steam trap. In addition, the improved steam trap apparatus allows for real-time data collection during sterilization and other operations.

    Abstract translation: 提供了一种用于从蒸汽/液体系统中除去冷凝物和不需要的气体同时防止蒸汽损失的装置和方法。 蒸汽疏水装置用有效，可控和可编程的疏水阀代替自动阀式疏水阀。 此外，改进的疏水装置允许在灭菌和其他操作期间实时数据收集。

    SOLID STATE FORMS OF ALISKIREN COMPOUNDS
    30.
    发明申请
    SOLID STATE FORMS OF ALISKIREN COMPOUNDS 审中-公开
    阿利昔宁化合物的固体状态

    公开(公告)号：WO2010091277A2

    公开(公告)日：2010-08-12

    申请号：PCT/US2010/023356

    申请日：2010-02-05

    Applicant: TEVA PHARMACEUTICAL INDUSTRIES LTD. ,  TEVA PHARMACEUTICALS USA, INC. ,  FINKELSTEIN, Nina ,  MITTELMAN, Ariel

    Inventor： FINKELSTEIN, Nina ,  MITTELMAN, Ariel

    IPC: A61K31/165 ,  C07C237/22

    CPC classification number: C07C231/24 ,  C07C237/22

    Abstract: The invention relates to solid states of pharmaceutically acceptable compounds of aliskiren, and processes for preparation thereof. The invention further provides pharmaceutical formulations comprising the amorphous or crystalline forms of pharmaceutically acceptable compounds of aliskiren and processes thereof; and a method of inhibiting renin for treating hypertension.

    Abstract translation: 本发明涉及阿利吉仑的药学上可接受的化合物的固态及其制备方法。 本发明进一步提供包含阿利吉仑的药学上可接受的化合物的无定形或结晶形式的药物制剂及其制备方法; 以及抑制肾素治疗高血压的方法。

Patent Agency Ranking